Can a common diabetes drug make arteries younger? VA launches new trial

NCT ID NCT06745063

Recruiting now Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether empagliflozin, a drug used for diabetes, can make arteries less stiff in veterans with obesity. Fifty participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in arterial stiffness using a standard test. The goal is to see if this drug can improve blood vessel health beyond its usual use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (a diabetes drug being tested for artery health)
What this could lead to: If it works, this could point toward a new way to improve blood vessel health in people with obesity, potentially reducing heart risks.
What could go wrong: This is a small, early-phase trial with only 50 participants. The drug may not improve artery stiffness, and results may not apply to people without obesity or with other health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY VASCULAR HEALTH

Contacts and locations

Locations

Harry S. Truman Memorial, Columbia, MO
RECRUITING

Columbia, Missouri, 65201-5275, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.